A specific mechanism of nonspecific inhibition

Journal of Medicinal Chemistry

Volumn 46, Issue 20, 2003, Pages 4265-4272

  McGovern, Susan L ^a   Helfand, Brian T ^a   Feng, Brian ^b   Shoichet, Brian K ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; GREEN FLUORESCENT PROTEIN; TRITON X 100;

ARTICLE; CENTRIFUGATION; ELECTRON MICROSCOPY; ENZYME INHIBITION; GEL ELECTROPHORESIS; MOLECULAR INTERACTION; PROTEIN DENATURATION; PROTEIN FOLDING; THERMODYNAMICS; THERMOSTABILITY;

BETA-LACTAMASES; CENTRIFUGATION; ENZYME INHIBITORS; FLUORESCENCE; HETEROCYCLIC COMPOUNDS; INHIBITORY CONCENTRATION 50; LIGHT; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, SCANNING; OCTOXYNOL; SCATTERING, RADIATION; THERMODYNAMICS;

EID: 0141792701     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030266r     Document Type: Article

References (21)

1. Sun, L.; Tran, N.; Tang, F.; App, H.; Hirth, P.; McMahon, G.; Tang, C. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J. Med. Chem. 1998, 41, 2588-2603.
2. Boehm, H. J.; Boehringer, M.; Bur, D.; Gmuender, H.; Huber, W.; Klaus, W.; Kostrewa, D.; Kuehne, H.; Luebbers, T.; Meunier-Keller, N.; Mueller, F. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J. Med. Chem. 2000, 43, 2664-2674,
3. Rishton, G. M. Reactive compounds and in vitro false positives in HTS. Drug Discovery Today 1997, 2, 382-384.
4. Bajorath, J. Integration of virtual and high-throughput screening. Nat. Rev. Drug Discovery 2002, 1, 882-894.
5. Erlanson, D. A.; Lam, J. W.; Wiesmann, C.; Luong, T. N.; Simmons, R. L.; DeLano, W. L.; Choong, I. C.; Burdett, M. T.; Flanagan, W. M.; Lee, D.; Gordon, E. M.; O'Brien, T. In situ assembly of enzyme inhibitors using extended tethering. Nat. Biotechnol. 2003, 21, 308-314.
6. Lingameneni, R.; Vysotskaya, T. N.; Duch, D. S.; Hemmings, H. C., Jr. Inhibition of voltage -dependent sodium channels by Ro 31-8220, a "specific" protein kinase C inhibitor. FEBS Lett. 2000, 473, 265-268.
7. Soltoff, S. P. Rottlerin is a mitochondrial uncoupler that decreases cellular ATP levels and indirectly blocks protein kinase Cdelta tyrosine phosphorylation. J. Biol. Chem. 2001, 276, 37986-37992.
8. Conseil, G.; Perez-Victoria, J. M.; Jault, J. M.; Gamarro, F.; Goffeau, A.; Hofmann, J.; Di Pietro, A. Protein kinase C effectors bind to multidrug ABC transporters and inhibit their activity. Biochemistry 2001, 40, 2564-2571.
9. Davies, S. P.; Reddy, H.; Caivano, M.; Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 2000, 351, 95-105.
10. Roche, O.; Schneider, P.; Zuegge, J.; Guba, W.; Kansy, M.; Alanine, A.; Bleicher, K.; Danel, F.; Gutknecht, E. M.; Rogers-Evans, M.; Neidhart, W.; Stalder, H.; Dillon, M.; Sjogren, E.; Fotouhi, N.; Gillespie, P.; Goodnow, R.; Harris, W.; Jones, P.; Taniguchi, M.; Tsujii, S.; von Der Saal, W.; Zimmermann, G.; Schneider, G. Development of a Virtual Screening Method for Identification of "Frequent Hitters" in Compound Libraries. J. Med. Chem. 2002, 45, 137-142.
11. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
12. Muegge, I.; Heald, S. L.; Brittelli, D. Simple selection criteria for drug-like chemical matter. J. Med. Chem. 2001, 44, 1841-1846.
13. Frimurer, T. M.; Bywater, R.; Naerum, L.; Lauritsen, L. N.; Brunak, S. Improving the odds in discriminating "drug-like" from "non drug-like" compounds. J. Chem. Inf. Comput. Sci. 2000, 40, 1315-1324.
14. Xu, J.; Stevenson, J. Drug-like index: a new approach to measure drug-like compounds and their diversity. J. Chem. Inf. Comput. Sci. 2000, 40, 1177-1187.
15. Oprea, T. I. Property distribution of drug-related chemical databases. J. Comput.-Aided Mol. Des. 2000, 14, 251-264.
16. Walters, W. P.; Namchuk, M. Designing screens: How to make your hits a hit. Nat. Rev. Drug Discovery 2003, 2, 259-266.
17. McGovern, S. L.; Caselli, E.; Grigorieff, N.; Shoichet, B. K. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem. 2002, 45, 1712-1722.
18. McGovern, S. L.; Shoichet, B. K, Kinase inhibitors: Not just for kinases anymore. J. Med. Chem. 2003, 46, 1478-1483.
19. Morandi, F.; Caselli, E.; Morandi, S.; Focia, P. J.; Blazquez, J.; Shoichet, B. K.; Prati, F. Nanomolar inhibitors of AmpC β-lactamase. J. Am. Chem. Soc. 2003, 125, 685-695.
20. Wang, X.; Minasov, G.; Shoichet, B. K. Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. J. Mol. Biol. 2002, 320, 85-95.
21. Weston, G. S.; Blazquez, J.; Baquero, F.; Shoichet, B. K. Structure-based enhancement of boronic acid-based inhibitors of AmpC β-lactamase. J. Med. Chem. 1998, 41, 4577-4586.